AU2009316326A1 - Method for treating Parkinson' s disease using filamentous bacteriophage - Google Patents

Method for treating Parkinson' s disease using filamentous bacteriophage Download PDF

Info

Publication number
AU2009316326A1
AU2009316326A1 AU2009316326A AU2009316326A AU2009316326A1 AU 2009316326 A1 AU2009316326 A1 AU 2009316326A1 AU 2009316326 A AU2009316326 A AU 2009316326A AU 2009316326 A AU2009316326 A AU 2009316326A AU 2009316326 A1 AU2009316326 A1 AU 2009316326A1
Authority
AU
Australia
Prior art keywords
bacteriophage
antibody
filamentous
synuclein
filamentous bacteriophage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009316326A
Other languages
English (en)
Inventor
Haim M. DIMANT
Beka Solomon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of AU2009316326A1 publication Critical patent/AU2009316326A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2009316326A 2008-11-24 2009-11-24 Method for treating Parkinson' s disease using filamentous bacteriophage Abandoned AU2009316326A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11744608P 2008-11-24 2008-11-24
US61/117,446 2008-11-24
PCT/US2009/065659 WO2010060073A2 (en) 2008-11-24 2009-11-24 Method for treating parkinson's disease

Publications (1)

Publication Number Publication Date
AU2009316326A1 true AU2009316326A1 (en) 2010-05-27

Family

ID=41572327

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009316326A Abandoned AU2009316326A1 (en) 2008-11-24 2009-11-24 Method for treating Parkinson' s disease using filamentous bacteriophage

Country Status (16)

Country Link
US (1) US20110286970A1 (enExample)
EP (2) EP2478911A1 (enExample)
JP (1) JP2012509672A (enExample)
KR (1) KR20110091778A (enExample)
CN (1) CN102223887B (enExample)
AU (1) AU2009316326A1 (enExample)
BR (1) BRPI0921557A2 (enExample)
CA (1) CA2744339A1 (enExample)
CO (1) CO6390112A2 (enExample)
IL (1) IL213120A0 (enExample)
MX (1) MX2011005430A (enExample)
NZ (1) NZ592928A (enExample)
RU (1) RU2011125971A (enExample)
SG (1) SG171791A1 (enExample)
WO (1) WO2010060073A2 (enExample)
ZA (1) ZA201104701B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE555128T1 (de) 2006-11-30 2012-05-15 Res Dev Foundation Verbesserte immunglobulin-bibliotheken
WO2009143470A1 (en) * 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Method for treating disease characterized by plaque
CA2829223A1 (en) 2011-03-11 2012-09-20 Beka Solomon Method for treating neurodegenerative tauopathy
EP2736522A1 (en) 2011-07-27 2014-06-04 Neurophage Pharmaceuticals, Inc. Process for the production of filamentous bacteriophage
CN104093414A (zh) * 2011-11-29 2014-10-08 神经噬菌体制药股份有限公司 噬菌体的p3作为淀粉样蛋白结合剂的用途
TWI613212B (zh) 2012-10-02 2018-02-01 波克萊拉生物科技股份有限公司 作爲澱粉樣蛋白結合劑之ｇ３ｐ融合蛋白
AU2014274253B2 (en) 2013-05-28 2018-06-14 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
EA201791212A1 (ru) 2014-12-03 2018-01-31 Проклара Байосайенсиз, Инк. Полипептиды, содержащие аминокислотную последовательность модифицированного бактериофага g3p, в которой отсутствует сигнал гликозилирования

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2344189T3 (es) * 1999-09-03 2010-08-20 RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. Agentes, composiciones y metodos que los utilizan utiles en el tratamiento o la prevencion de la enfermedad de alzheimer.
AU2002223886A1 (en) * 2000-11-24 2002-06-03 Isis Innovation Limited Mixed fibrils
ES2392247T3 (es) * 2002-03-05 2012-12-07 Ramot At Tel-Aviv University Ltd. Compuesto inmunizante y método para inducir una respuesta inmune contra el sitio de escisión de la beta-secretasa de la proteína precursora de amiloide
GB0305918D0 (en) * 2003-03-14 2003-04-23 Glaxo Group Ltd Novel compounds
FR2855178B1 (fr) * 2003-05-20 2005-08-05 Centre Nat Rech Scient Peptides modulateurs de l'activite du facteur de transcription engrailed
EP1853299A4 (en) * 2005-01-14 2009-11-11 Univ California COMPOSITIONS AND METHODS FOR INHIBITING THE PRESENCE OF DRUGS AND DIAGNOSING OR TREATING DRUG-INDUCED DISEASES
ES2363203T3 (es) * 2005-02-01 2011-07-26 Ramot At Tel-Aviv University Ltd. Método para tratar una inflamación asociada a depósitos amiloides y una inflamación cerebral que implica una microglia activada.
BRPI0707871A2 (pt) * 2006-02-15 2011-05-10 Ramot At Tel Aviv University veÍculos de exibiÇço de fago, composiÇço farmacÊutica ,e, mÉtodos para o tratamento ou a inbiÇço e para o diagnàsticos de uma doenÇa, distébio ou condiÇço cerebral
CA2659032A1 (en) * 2006-07-21 2008-01-24 Ramot At Tel Aviv University Ltd. Method for inhibiting or treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates
WO2009143470A1 (en) * 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Method for treating disease characterized by plaque

Also Published As

Publication number Publication date
JP2012509672A (ja) 2012-04-26
US20110286970A1 (en) 2011-11-24
ZA201104701B (en) 2012-09-26
KR20110091778A (ko) 2011-08-12
WO2010060073A3 (en) 2010-09-02
BRPI0921557A2 (pt) 2019-09-24
NZ592928A (en) 2012-12-21
SG171791A1 (en) 2011-07-28
IL213120A0 (en) 2011-07-31
CO6390112A2 (es) 2012-02-29
RU2011125971A (ru) 2012-12-27
WO2010060073A2 (en) 2010-05-27
EP2358377A2 (en) 2011-08-24
CA2744339A1 (en) 2010-05-27
HK1162964A1 (en) 2012-09-07
CN102223887B (zh) 2013-11-06
EP2478911A1 (en) 2012-07-25
MX2011005430A (es) 2011-10-28
CN102223887A (zh) 2011-10-19

Similar Documents

Publication Publication Date Title
EP2478911A1 (en) Method for treating Parkinson's disease using filamentous bacteriophage
Cascella et al. Effects of oligomer toxicity, fibril toxicity and fibril spreading in synucleinopathies
Caruso Bavisotto et al. Extracellular vesicle-mediated cell–cell communication in the nervous system: Focus on neurological diseases
Yuan et al. Exosomes in Parkinson’s disease: current perspectives and future challenges
EP2054515B1 (en) Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates
Pimpinelli et al. The scrapie prion protein is present in flotillin‐1‐positive vesicles in central‐but not peripheral‐derived neuronal cell lines
US20220403021A1 (en) Targeting Synaptogyrin-3 in Tauopathy Treatment
Spencer et al. Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders
US8980547B2 (en) Method for treating neurodegenerative tauopathy
JP2009529320A (ja) 脳への送達のための抗体および免疫複合体のバインダーとしてのプロテインａをディスプレイする繊維状バクテリオファージ
EP2303315A1 (en) Method for treating disease characterized by plaque
AU2014274253A1 (en) Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
Vitale et al. Intramuscular injection of vectorized-scFvMC1 reduces pathological tau in two different tau transgenic models
Teng et al. Efficient amyloid-β degradation in Alzheimer’s disease using SPYTACs
Rene et al. Extracellular vesicles efficiently deliver survival motor neuron protein to cells in culture
HK1162964B (en) Method for treating parkinson' s disease using filamentous bacteriophage
US20260048090A1 (en) M13 bacteriophages displaying peptide motifs targeting amyloid-beta, methods and uses thereof
Peres Role for lipids in the cellular transmission of α-synuclein
Ross The Development of Antibody Loaded Liposomes for the Treatment of Alzheimer's Disease
Tuck The mechanisms of tau entry to the cytosol
Solomon In Vivo Targeting of Amyloid Plaques Via Intranasal Administration of Phage Anti-β-Amyloid Antibodies
Schmidt The immunomodulatory effects of Interferon ß in the ApdE9 transgenic mouse model: a potential therapeutic strategy against Alzheimer's disease
Evangelista et al. Tandem Detergent-Extraction and Immunoprecipitation of Proteinopathy (TDiP): Scalable Enrichment of ALS-Associated TDP-43 Aggregates

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application